Clinical Trial Results:
A Phase III Study to Assess the Tolerability and Efficacy of MK-0822 (Odanacatib) in Reducing the Risk of Bone Metastases and Prolonging Disease-Free Survival in Women with Breast Cancer
Spanish title:
“Estudio de Fase III para evaluar la tolerabilidad y eficacia de MK-0822 (Odanacatib) en la reducción del riesgo de desarrollar metástasis óseas y en la prolongación de la supervivencia libre de progresión en mujeres con cáncer de mama”
Summary
|
|
EudraCT number |
2008-002119-42 |
Trial protocol |
ES |
Global completion date |
08 Sep 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 May 2019
|
First version publication date |
18 May 2019
|
Other versions |
|
Summary report(s) |
Cancelled/ Withdrawn Memo |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.